Clinical pharmacological studies have shown that the uptake of DA by monoaminergic neurons mediated by VMAT-2 can prevent the oxidation of DA, and the overexpression of VMAT-2 may provide a potential target for neuroprotective therapy in various psychiatric diseases (Segura et al., 2019). This evidence concerns the gene SLC18A2 and psychiatric disorder.